AI Article Synopsis
- A 43-year-old woman with pancytopenia and thymoma continued to need weekly blood transfusions after undergoing thymectomy, and didn't improve with prednisone treatment.
- She was then treated with cyclosporine (10 mg/kg/day) and a lower dose of prednisone (20 mg/day) for a month, which helped restore her blood parameters.
- Thirty months later, she remains healthy and has stable blood counts.
Article Abstract
In a 43-year-old woman, pancytopenia accompanying thymoma persisted after thymectomy, requiring weekly blood transfusions, and did not respond to prednisone 50 mg/day. Cyclosporine 10 mg/kg/day plus prednisone 20 mg/day for a month gradually corrected the blood parameters. Thirty months later the patient is well and haematologically stable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/14017439509107222 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glucocorticoid dosing and implications for vaccination: Evolution of global definitions.
Clin Infect Dis
December 2024
National Centre for Immunisation Research and Surveillance, Westmead, New South Wales.
Despite widespread adoption of "high-dose" glucocorticoid definitions across international immunisation guidelines (i.e., prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear.
View Article and Find Full Text PDFUnveiling the Uncommon: A Case Report of Horner's Syndrome as a Rare Glimpse Into Giant Cell Arteritis.
Case Rep Neurol Med
December 2024
Department of Neurology, Mayo Clinic, Phoenix, Arizona, USA.
Giant cell arteritis (GCA) is an inflammatory vasculitis affecting large and medium-sized arteries, leading to complications such as arterial dissection, blindness, and stroke. Rarely, GCA presents with Horner's syndrome due to sympathetic neuron involvement from arterial inflammation. This case report discusses an 82-year-old female with hypertension, atrial fibrillation, and arthritis who presented with a 24 h history of right eye ptosis, blurred vision, dizziness, and aching eye pain.
View Article and Find Full Text PDFEfficacy and safety of guselkumab in patients with active lupus nephritis: results from a Phase 2, randomized, placebo-controlled study.
Rheumatology (Oxford)
December 2024
The Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, The Feinstein Institutes for Medical Research, Manhasset, NY, USA.
Objective: Evaluate the efficacy and safety of guselkumab, an interleukin (IL)-23 inhibitor, in a Phase 2, multicentre, randomized, double-blind, placebo-controlled study of patients with active lupus nephritis (LN).
Methods: Adults (18-75 years) with active LN (Class III-IV proliferative nephritis [kidney biopsy] and urine protein-to-creatinine ratio [UPCR)] of ≥ 1 mg/mg despite standard-of-care therapy) were randomized (1:1; planned sample = 60) to receive intravenous infusions of guselkumab 400 mg or placebo at Weeks 0, 4, and 8, then subcutaneous injections (guselkumab 200 mg or placebo) at Week12 and every 4 weeks through Week48 in addition to their background therapy. The primary end point was achievement of ≥ 50% decrease in proteinuria from baseline at Week24.
Optimal Timing for Corticosteroid Therapy in Idiopathic Granulomatous Mastitis: A Retrospective Analysis Highlighting Early Intervention Efficacy.
J Inflamm Res
November 2024
Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Background: Idiopathic granulomatous mastitis (IGM) is a chronic breast condition known for its aggressive nature and tendency for persistence and recurrence. Steroids are commonly used as the first-line treatment for IGM, but issues such as the optimal timing, and duration of treatment remain debated.
Methods: We retrospectively analyzed 343 IGM cases treated at the Third People's Hospital of Chengdu from September 2012 to September 2023.
Sustained Drug-Free Remission in Giant Cell Arteritis.
Rheumatology (Oxford)
November 2024
Department of Rheumatology. Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Objetive: To evaluate the frequency and timing of sustained drug-free remission (SDFR) in patients with giant cell arteritis (GCA) and to identify potential predictive factors of this outcome.
Methods: Retrospective review of all patients included in the large Spanish multicentre registry for GCA (ARTESER) with at least two years of follow-up. SDFR was defined as the absence of typical signs, symptoms, or other features of active GCA for ≥12 months after discontinuation of treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!